SCHEMBL2845348

SCHEMBL2845348

CCN1CCN(Cc2ccc(C(=O)Nc3ccc(Oc4ncnc5[nH]cnc45)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 9/20 0.63
MAP4K2 Q12851 9/20 0.63
MAPK14 Q16539 8/20 0.63
FES P07332 5/20 0.61
FER P16591 5/20 0.61
MAP3K20 Q9NYL2 3/20 0.61
DDR1 Q08345 4/20 0.58
HCK P08631 5/20 0.57
NR2C2 P49116 4/20 0.57
GCK P35557 2/20 0.55
MAP4K4 O95819 2/20 0.55
ABL1 P00519 2/20 0.55
RAF1 P04049 2/20 0.55
LYN P07948 2/20 0.55
SRC P12931 2/20 0.55
EPHA2 P29317 2/20 0.55
EPHB2 P29323 2/20 0.55
FLT3 P36888 2/20 0.55
CSK P41240 2/20 0.55
ABL2 P42684 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851874 0.91 SRC (0.67) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL30692254 0.89 MAP3K7 (0.79) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL14689771 0.89 MAP3K7 (0.79) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL23353589 0.82 MAP3K7 (0.52) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL12999411 0.81 ABL1 (0.52) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL22457231 0.79 MAPK14 (0.79) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL2848857 0.79 MAPK14 (0.73) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL20570128 0.77 MAP3K7 (0.57) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL30692261 0.77 MAP3K7 (1.00) MAP3K7MAP4K2MAPK14FESFER
SCHEMBL14690002 0.77 MAP3K7 (1.00) MAP3K7MAP4K2MAPK14FESFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592433-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-11-26 US claimed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US claimed
US-20100130476-A1 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-27 US claimed
WO-2010056907-A2 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-20 WO claimed
EP-1940844-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-09-30 EP claimed
EP-1940844-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-07-09 EP claimed
WO-2007053343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-05-10 WO claimed
US-8592433-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-11-26 US disclosed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US disclosed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US disclosed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US disclosed
US-20100130476-A1 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-27 US disclosed
WO-2010056907-A2 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-20 WO disclosed
EP-1940844-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-09-30 EP disclosed
EP-1940844-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-07-09 EP disclosed
WO-2007053343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-05-10 WO disclosed
WO-2007053343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS SYK, SRC, FYN MAP3K7 50/4885MAP4K2 38/4885MAPK14 303/4885
US-20100130476-A1 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION IAPP, PNLIP, GPR119 MAP3K7 1968/4885MAP4K2 2451/4885MAPK14 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.